Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia

Initial Discussion Held with Clinical Investigator at Australia’s Biggest Cancer Hospital

Related Keywords

United States ,Melbourne ,Victoria ,Australia ,Australian ,Mark Rosenthal ,Peter Mac ,James Nathanielsz ,Company Mechanism Of Action ,Peter Mac Cancer Center ,Propanc Biopharma Inc ,Drug Administration ,Initial Discussion Held ,Clinical Investigator ,Biggest Cancer ,Propanc Biopharma ,Professor Mark Rosenthal ,Study Investigator ,Chief Executive ,Australian Government ,Advance Overseas Finding ,Science Australia ,Drug Designation ,Private Securities Litigation Reform Act ,Press Release , ,